Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Mammalian cell-cycle control by antimitogenic signals involves p21Cip1/WAF1 (refs 1-4), p27Kip1 (refs 5, 6) and p57Kip2 (refs 7, 8), a family of proteins that bind to and inhibit cyclin-dependent kinases (CDKs) required for initiation of S phase. The protein p21 also binds to the DNA polymerase delta processivity factor, proliferating-cell nuclear antigen (PCNA), and inhibits in vitro PCNA-dependent DNA replication. The CDK and PCNA inhibitory activities of p21 are shown here to be functionally independent and to reside in separate protein domains. The PCNA binding and inhibitory activities, which are not observed with p27 or p57, reside in the C-terminal domain of p21, whereas the CDK inhibitory activity resides in the conserved N-terminal domains of these proteins. When separately overexpressed in mammalian cells, the CDK and PCNA inhibitory domains prevent DNA replication, demonstrating a dual function of p21 as a cell-cycle inhibitor in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“P21 functions primarily by binding to and inhibiting CDKs, and in addition, p21 halts the cell cycle by blocking PCNA, which is required for DNA replication.150, 151”
From Census and evaluation of p53 target genes (2017) · cites this paper as [150]
In the citing paper
“P21 functions primarily by binding to and inhibiting CDKs, and in addition, p21 halts the cell cycle by blocking PCNA, which is required for DNA replication.150, 151”
From Census and evaluation of p53 target genes (2017) · cites this paper as [150]
In the citing paper
“While the p21/PCNA ratio was reported to never exceed a 1:1 ratio in cells [37,38], a ratio of at least 10:1 is required to block DNA repair by nucleotide excision repair (NER) in vitro [38,39,40,41].”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [38]
In the citing paper
“While the p21/PCNA ratio was reported to never exceed a 1:1 ratio in cells [37,38], a ratio of at least 10:1 is required to block DNA repair by nucleotide excision repair (NER) in vitro [38,39,40,41].”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [38]
In the citing paper
“When assessing the effect of p21 on PCNA-dependent DNA synthesis in cells, several reports showed a limited or null effect of p21–PCNA interaction on DNA replication [38,45,46,47,48,49,50,51].”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [38]
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
A short amino acid sequence able to specify nuclear location
Kalderon, D., Roberts, B. L., Richardson, W. D., & Smith, A. E. (1984) · Cell · doi:10.1016/0092-8674(84)90457-4 · Cited by 2,507
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Self-citationp27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
Toyoshima, H., & Hunter, T. (1994) · Cell · doi:10.1016/0092-8674(94)90573-8 · Cited by 2,043
The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
Waga, S., Hannon, G. J., Beach, D., & Stillman, B. (1994) · Nature · doi:10.1038/369574a0 · Cited by 1,655
Matsuoka, S., Edwards, M. C., Bai, C., Parker, S., Zhang, P., Baldini, A., Harper, J. W., & Elledge, S. J. (1995) · Genes & Development · doi:10.1101/gad.9.6.650 · Cited by 952
Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., & Sherr, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90360-o · Cited by 897
Lee, M. H., Reynisdóttir, I., & Massagué, J. (1995) · Genes & Development · doi:10.1101/gad.9.6.639 · Cited by 889
Self-citation
Research works printed but not linked: 1
- Kelman, Z., Naktinis, V. & O'Donnell, M. Meth. Enzym. (in the press).
Cited by
Items 201–300 of 548
Bahl, R., Arora, S., Nath, N., Mathur, M., Shukla, N. K., & Ralhan, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203325 · Cited by 69
“Either the N-terminal CDK or the C-terminal PCNA binding region of p21waf1/cip1 is su cient to inhibit DNA replication when expressed in cells (Chen et al., 1995; Luo et al., 1995).”
BackgroundExpression of cyclin-dependent kinase inhibitor p21 in human liver
Crary, G. S., & Albrecht, J. H. (1998) · Hepatology · doi:10.1002/hep.510280320 · Cited by 62
ZHANG, H., HOU, Y., & LIN, S. (2006) · Journal of Eukaryotic Microbiology · doi:10.1111/j.1550-7408.2005.00085.x · Cited by 61
“To regulate the cell cycle, PCNA interacts with cdc2 and its inhibitor p21 (Brott et al. 1993; Chuang et al. 1997; Li et al. 1994; Luo, Hurwitz, and Massague 1995), as well as p53 and p27 (Jing, Nan, and Hu 2005).”
BackgroundCell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle
Brian, T. Z. (2000) · Frontiers in bioscience · doi:10.2741/zafonte · Cited by 65
“(PCNA), a processivity subunit of the DNA polymerase δ holoenzyme (68-70, 72, 73).”
BackgroundChen, L., Li, J., Fan, Y., Qiu, J., Cao, L., Laurent, R., Mignani, S. M., Caminade, A., Majoral, J., & Shi, X. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00458 · Cited by 65
Probing protein structure using biochemical and biophysical methods
Kriwacki, R. W., Wu, J., Tennant, L. L., Wright, P. E., & Siuzdak, G. E. (1997) · Journal of Chromatography A · doi:10.1016/s0021-9673(97)00527-x · Cited by 65
Hromas, R., Ye, H., Spinella, M. J., Dmitrovsky, E., Xu, D., & Costa, R. H. (1999) · Cell and Tissue Research · doi:10.1007/s004410051365 · Cited by 59
Dandrea, T., Hellmold, H., Jonsson, C., Zhivotovsky, B., Hofer, T., Wärngård, L., & Cotgreave, I. A. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2003.12.014 · Cited by 64
Yamato, K., Koseki, T., Ohguchi, M., Kizaki, M., Ikeda, Y., & Nishihara, T. (1997) · Molecular Endocrinology · doi:10.1210/me.11.8.1044 · Cited by 60
Gibbs, E., Kelman, Z., Gulbis, J. M., O'Donnell, M., Kuriyan, J., Burgers, P. J., & Hurwitz, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.4.2373 · Cited by 58
Self-citationSimboeck, E., Sawicka, A., Zupkovitz, G., Senese, S., Winter, S., Dequiedt, F., Ogris, E., Di Croce, L., Chiocca, S., & Seiser, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.184481 · Cited by 57
Sinicrope, F. A., Roddey, G., Lemoine, M., Ruan, S., Stephens, L. C., Frazier, M. L., Shen, Y., & Zhang, W. (1998) · PubMed · Cited by 56
p21: structure and functions associated with cyclin-CDK binding
Ball, K. L. (1997) · Springer eBooks · doi:10.1007/978-1-4615-5371-7_10 · Cited by 62
Kim, C., Lee, J. H., Kim, S., Sethi, G., & Ahn, K. S. (2015) · Oncotarget · doi:10.18632/oncotarget.3004 · Cited by 57
“It negatively modulates cell cycle progression by inhibiting the activities of cyclin E/CDK2 and cyclin D/ CDK4 complexes and blocks DNA replication by binding to proliferating cell nuclear antigen [42].”
BackgroundMukunthan, K. S., Satyan, R. S., & Patel, T. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.07.021 · Cited by 68
Synthetic Cyclin Dependent Kinase Inhibitors
Hajdúch, M., Havlíèek, L., Veselý, J., Novotný, R., Mihál, V., & Strnad, M. (1999) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4811-9_37 · Cited by 55
Heinzel, P. A., Balaram, P., & Bernard, H. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19961115)68:4<428::aid-ijc5>3.0.co;2-2 · Cited by 70
Functional Analysis of a p21 Mutant (Arg94→ Trp) Identified in a Human Breast Carcinoma
Balbín, M., Hannon, G. J., Pendás, A. M., Ferrando, A. A., Vizoso, F., Fueyo, A., & López-Otín, C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.26.15782 · Cited by 55
“…altered in the p21R94W mutant is consistent with results from different groups demonstrating that the CDK and PCNA inhibitory activities of p21 are functionally independent and reside in separate protein domains (Chen et al., 1995; Luo et al., 1995; Nakanishi et al., 1995; Warbrick et al., 1995).”
ResultEffect of p21waf1/cip1 transgene on radiation induced apoptosis in T cells
Fotedar, R., Brickner, H., Saadatmandi, N., Rousselle, T., Diederich, L., Munshi, A., Jung, B. H., Reed, J. C., & Fotedar, A. (1999) · Oncogene · doi:10.1038/sj.onc.1202693 · Cited by 67
“The Cterminal region of p21 inhibits DNA elongation in vitro by binding PCNA (Chen et al., 1996; Luo et al., 1995). p21 expression is implicated in cell cycle arrest (Brugarolas et al., 1995; Deng et al., 1995), in withdrawal of cells from the cell cycle during di erentiation (Halevy et al., 1995)…”
BackgroundBi, M., Yu, H., Huang, B., & Tang, C. (2017) · Gene · doi:10.1016/j.gene.2017.05.049 · Cited by 55
Naderi, J., Lopez, C., & Pandey, S. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.08.006 · Cited by 62
Campagne, M. V. L., & Gill, R. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00580-0 · Cited by 54
Role for Cyclin A-dependent Kinase in DNA Replication in Human S Phase Cell Extracts
Fotedar, A., Cannella, D., FITZGERALD, P. J., Rousselle, T., Gupta, S., Dorée, M., & Fotedar, R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31627 · Cited by 57
Cell cycle regulation: Repair and regeneration in acute renal failure
Price, P. M., Megyesi, J. K., & Safirstein, R. L. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.761_8.x · Cited by 59
Histone deacetylases, transcriptional control, and cancer
Cress, W. D., & Seto, E. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200007)184:1<1::aid-jcp1>3.0.co;2-7 · Cited by 621
Frimerman, A., Welch, P. J., Jin, X., Eigler, N. L., Yei, S., Forrester, J. S., Honda, H., Makkar, R., Barber, J. R., & Litvack, F. (1999) · Circulation · doi:10.1161/01.cir.99.5.697 · Cited by 57
Zhu, H., & Gooderham, N. J. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj146 · Cited by 54
“In addition, the ability of p21Cip1/WAF1 to interact with proliferating cell nuclear antigen (Chen et al., 1995; Luo et al., 1995), a protein functioning to provide replicative polymerases with the high processivity required to duplicate an entire genome (Johnson and O’Donnell, 2005; Majka and…”
BackgroundStivala, L. A., Riva, F., Cazzalini, O., Savio, M., & Prosperi, E. (2001) · Oncogene · doi:10.1038/sj.onc.1204132 · Cited by 57
“…(i) CDK inhibition (Sherr and Roberts, 1999); and (ii) binding to the proliferating cell nuclear antigen (PCNA) (Goubin and Ducommun, 1995; Luo et al., 1995; Nakanishi et al., 1995; Fotedar et al., 1996; Chen et al., 1996b), the co-factor of DNA polymerases d and e (Jo nsson and HuÈ…”
BackgroundMomand, J., & Zambetti, G. P. (1997) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19970301)64:3<343::aid-jcb1>3.0.co;2-v · Cited by 168
Complex Formation between Hepatitis C Virus Core Protein and p21Waf1/Cip1/Sdi1
Wang, F., Yoshida, I., Takamatsu, M., Ishido, S., Fujita, T., Oka, K., & Hotta, H. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2970 · Cited by 50
Bennett, S. E., Sung, J.-S., & Mosbaugh, D. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106212200 · Cited by 49
Naderi, S., Wang, J. Y. J., Chen, T.-T., Gützkow, K. B., & Blomhoff, H. K. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-06-0501 · Cited by 55
“Several reports have suggested that the negative effect of p21Cip1 on DNA synthesis relies primarily on its ability to inhibit Cdk-cyclin–dependent pathways (Luo et al., 1995; Nakanishi et al., 1995a, 1995b; Ogryzko et al., 1997).”
BackgroundThe Growth-Regulatory Role of p21 (WAF1/CIP1)
Gartel, A. L., & Tyner, A. L. (1998) · Progress in molecular and subcellular biology · doi:10.1007/978-3-642-72149-6_4 · Cited by 57
Corroyer, S., Nabeyrat, E., & Clément, A. (1997) · Endocrinology · doi:10.1210/en.138.9.3677 · Cited by 53
Mechanism of Stimulation of Human DNA Ligase I by the Rad9-Rad1-Hus1 Checkpoint Complex
Wang, W., Lindsey-Boltz, L. A., Sancar, A., & Bambara, R. A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602289200 · Cited by 49
Lee, H., Baek, S., Lee, J., Kim, C., Ko, J., Lee, S., Chinnathambi, A., Alharbi, S. A., Yang, W. M., Um, J., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051095 · Cited by 49
“It negatively modulates cell cycle progression by inhibiting the activities of cyclin D/CDK4 complexes and can block DNA replication by binding to proliferating cell nuclear antigen [16].”
Senescence and Apoptosis: Architects of Mammalian Development
Wanner, E., Thoppil, H., & Riabowol, K. T. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.620089 · Cited by 59
“The CDK inhibitory domain and PCNA binding domains of p21 are responsible for its main growth inhibition characteristics (Chen et al., 1995; Luo et al., 1995).”
BackgroundHalaschek-Wiener, J., Wacheck, V., Schlagbauer-Wadl, H., Wolff, K., Kloog, Y., & Jansen, B. (2000) · Molecular Medicine · doi:10.1007/bf03402049 · Cited by 47
Boussiotis, V. A., Chen, Z.-M., Zeller, J. C., Murphy, W. J., Berezovskaya, A., Narula, S. K., Roncarolo, M. G., & Blazar, B. R. (2001) · Blood · doi:10.1182/blood.v97.2.565 · Cited by 54
P21Cip1 induced by Raf is associated with increased Cdk4 activity in hematopoietic cells
Chang, F., & McCubrey, J. A. (2001) · Oncogene · doi:10.1038/sj.onc.1204564 · Cited by 56
“They di er from the other Cdk inhibitor gene family INK4 in that they harbor both the Cdk and cyclin binding sites (Chen et al., 1995, 1996; Luo et al., 1995; Nakanishi et al., 1995; Lin et al., 1996).”
BackgroundInhaled Asbestos Fibers Induce p53 Expression in the Rat Lung
Mishra, A., Liu, J. Y., Brody, A. R., & Morris, G. F. (1997) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.16.4.9115760 · Cited by 47
Le, H.-V., Minn, A. J., & Massagué, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504689200 · Cited by 51
Self-citationEffect of HIV-1 Vpr on Cell Cycle Regulators
Amini, S., Khalili, K., & Sawaya, B. E. (2004) · DNA and Cell Biology · doi:10.1089/104454904773819833 · Cited by 54
“The p21 protein, but not p27 or p57, also binds and inhibits proliferating cell nuclear antigen (PCNA), a subunit of DNA polymerase d , which has roles in DNA replication and repair (Luo et al. , 1995).”
Rottlerin: a multifaced regulator of keratinocyte cell cycle
Valacchi, G., Pecorelli, A., Mencarelli, M., Carbotti, P., Fortino, V., Muscettola, M., & Maioli, E. (2009) · Experimental Dermatology · doi:10.1111/j.1600-0625.2008.00816.x · Cited by 47
Cell cycle regulation: repair and regeneration in acute renal failure
Price, P. M., Megyesi, J. K., & Safirstein, R. L. (2003) · Seminars in Nephrology · doi:10.1016/s0270-9295(03)00087-1 · Cited by 45
“Similarly, p21 can also inhibit PCNA [38–42] and interfere with its role in DNA replication.”
BackgroundRetroviral Delivery of Peptide Modulators of Cellular Functions
Lorens, J. B., Bennett, M. K., Pearsall, D., Throndset, W., Rossi, A. B., Armstrong, R. J., Fox, B., Chan, E., Luo, Y., Masuda, E. S., et al. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0063 · Cited by 48
Self-citationHelper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics
Appleman, L. J., Tzachanis, D., Grader‐Beck, T., van Puijenbroek, A. A. F. L., & Boussiotis, V. A. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090000180 · Cited by 53
“This association of p21cip1 has been hypothesized to induce a brief arrest of the cycling cells to allow DNA repair [85, 86, 87].”
BackgroundSchepers, H., Geugien, M., Eggen, B. J. L., & Vellenga, E. (2003) · Leukemia · doi:10.1038/sj.leu.2403106 · Cited by 46
Wagayama, H., Shiraki, K., Sugimoto, K., Ito, T., Fujikawa, K., Yamanaka, T., Takase, K., & Nakano, T. (2002) · Human Pathology · doi:10.1053/hupa.2002.124724 · Cited by 46
Evidence for a p23 caspase-cleaved form of p27[KIP1] involved in G1 growth arrest
Loubat, A., Rochet, N., Turchi, L., Rezzonico, R., Far, D. F., Auberger, P., Rossi, B., & Ponzio, G. (1999) · Oncogene · doi:10.1038/sj.onc.1202668 · Cited by 49
“This observation is in total agreement with previous reports showing that the amino terminus of p27 is su cient to bind and to inhibit the cyclin/CDK2 complexes (Luo et al., 1995).”
ResultLu, D., Han, C. Q., & Wu, T. (2013) · Oncogene · doi:10.1038/onc.2013.69 · Cited by 45
“The growth-inhibitory action of p21 is attributed to the functions of the carboxy-terminal PCNA-binding domain as well as the amino-terminal CDK-cyclin inhibitory domain(41, 42).”
BackgroundRaucher, D., Moktan, S., Massodi, I., & Bidwell, G. L. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903158909 · Cited by 46
“Two classes of p21-derived peptides have been described: N-terminal peptides, which inhibit cyclin/Cdk activation, and C-terminal peptides, which interact with PCNA and inhibit DNA replication [11].”
BackgroundGene expression profile of butyrate-inhibited vascular smooth muscle cell proliferation
Ranganna, K., Yousefipour, Z., Yatsu, F. M., Milton, S. G., & Hayes, B. E. (2003) · Molecular and Cellular Biochemistry · doi:10.1023/a:1027383710582 · Cited by 45
“p21Waf1 also reacts with PCNA, independent of cdk and causes inhibition of DNA synthesis [40].”
BackgroundKeller, C., & Krude, T. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003073200 · Cited by 52
Kao, S., Lemoine, F. J., & Marriott, S. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004397200 · Cited by 50
Korkolopoulou, P. A., Kouzelis, K., Christodoulou, P. N., Papanikolaou, A., & Thomas-Tsagli, E. (1998) · Acta Neuropathologica · doi:10.1007/s004010050848 · Cited by 45
“(CIP)1, wild-type p53-activated fragment (WAF)1 and senescent cell-derived inhibitor (SDI)1] [10, 15, 38] is unique in this family of cdk inhibitors in that it plays a dural role at the G1 checkpoint, interacting independently with cyclin/cdk complexes and also with the DNA polymerase δreplicating factor, proliferatin…”
Backgroundp21 as a Transcriptional Co-Repressor of S-Phase and Mitotic Control Genes
Ferrándiz, N., Caraballo, J. M., García-Gutiérrez, L., Devgan, V., Rodríguez‐Paredes, M., Lafita‐Navarro, M. C., Bretones, G., Quintanilla, A., Muñoz-Alonso, M. J., Blanco, R. E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037759 · Cited by 52
“This indicates that the repressive activity of p21 is independent of the protein-protein interaction domain known to reside in the C-terminal region, as PCNA binding [42].”
BackgroundRodríguez-Vilarrupla, A., Jaumot, M., Abella, N., Canela-Canela, N., Brun, S., Díaz, C., Estanyol, J. M., Bachs, O., & Agell, N. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.16.7364-7374.2005 · Cited by 44
“Like other members of the CIP/KIP family, p21 contains conserved cyclin and cdk-binding domains near the amino terminus of the molecule (10, 20, 21, 34 , 39).”
BackgroundKnight-Krajewski, S., Welsh, C. F., Liu, Y., Lyons, L. S., Faysal, J. M., Yang, E. S.-H., & Burnstein, K. L. (2004) · Oncogene · doi:10.1038/sj.onc.1207708 · Cited by 46
“…of CDK2 activity. p21 may inhibit cell proliferation not only through decreasing CDK2 activity, but also through other mechanisms such as by interacting with proliferating cell nuclear antigen (PCNA) and decreasing DNA replication (Flores-Rozas et al., 1994; Waga et al., 1994; Luo et al., 1995).”
BackgroundHuang, Y., Zhu, Y., Yang, J., Pan, Q., Zhao, J., Song, M., Yang, C., Han, Y., Tang, Y., Wang, Q., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04676-1 · Cited by 45
“In addition, by binding to proliferating cell nuclear antigen (PCNA), p21 interferes with PCNA-dependent DNA polymerase activity, which is required for DNA replication and repair processes [19, 20].”
BackgroundLi, O., Ferreira, A. M., Otieno, S. B., 利民, L. X. 肖., Bashford, D., & Kriwacki, R. W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.244095 · Cited by 44
Enolase-1 serves as a biomarker of diagnosis and prognosis in hepatocellular carcinoma patients
Zhu, W., Li, H., Yan, Y., Chen, J., Chen, X., Ren, F., Ren, Z., & Cui, G. (2018) · Cancer Management and Research · doi:10.2147/cmar.s182183 · Cited by 43
“In addition, the gene set enrichment analysis was performed to predict the molecular mechanism of ENO1 action in HCC. Results: ENO1 was overexpressed in HCC tissues and associated with worse outcomes in terms of overall survival (OS) (P 0.01) and disease-free survival (P 0.01).”
BackgroundInfluentialQuo vadis Cardiac Glycoside Research?
Bejček, J., Jurášek, M., Spiwok, V., & Rimpelová, S. (2021) · Toxins · doi:10.3390/toxins13050344 · Cited by 46
Fernandes, D., Ravenhall, C. E., Harris, T., Tran, T., Vlahos, R., & Stewart, A. G. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705809 · Cited by 43
“…E2F-dependent transcription through direct binding to E2F (Shiyanov et al., 1996; Delavaine & La Thangue, 1999) and directly inhibits DNA replication by binding to the proliferating cell nuclear antigen (PCNA), a subunit of DNA polymerase d, without affecting DNA repair (Luo et al., 1995).”
Backgroundp300 Alters Keratinocyte Cell Growth and Differentiation through Regulation of p21Waf1/CIP1
Wong, P., Pickard, A., & McCance, D. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008369 · Cited by 46
“In contrast, the C-terminal domain of p21, which can bind and inhibit the DNA replication function of proliferating nuclear antigen (PCNA) is unique [7,8].”
BackgroundFezf1 and Fezf2 are required for olfactory development and sensory neuron identity
Eckler, M. J., McKenna, W. L., Taghvaei, S., McConnell, S. K., & Chen, B. (2011) · The Journal of Comparative Neurology · doi:10.1002/cne.22596 · Cited by 42
“…family (Wang et al., 1997, 2002, 2004), Mecp2 (Ronnett et al., 2003; Matarazzo et al., 2004), Dlx5 (Levi et al., 2003; Long et al., 2003), and KLF7 (Luo et al., 1995; Laub et al., 2001; Tanaka et al., 2002), function further downstream in OE development and regulate OSN maturation and axonal…”
BackgroundInfluentialTranscriptional Regulation of Neurogenesis in the Olfactory Epithelium
Nicolay, D. J., Doucette, J. R., & Nazarali, A. J. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9058-4 · Cited by 49
“How Runx1 prevents premature differentiation is unknown but may involve its ability to repress the expression of the cyclin dependent kinase inhibitor, p21 (Theriault et al., 2005), which is involved in cell cycle exit (Luo et al., 1995).”
BackgroundLe, N., & Richardson, D. R. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg042 · Cited by 41
Cistulli, C. A., & Kaufmann, W. K. (1998) · PubMed · Cited by 47
Downregulation of PCNA potentiates p21-mediated growth inhibition in response to hyperoxia
Gehen, S. C., Vitiello, P. F., Bambara, R. A., Keng, P. C., & O’Reilly, M. A. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00135.2006 · Cited by 44
p21 WAF1 Mutations and human malignancies
Shiohara, M., Koike, K., Komiyama, A., & Koeffler, H. P. (1997) · Leukemia & Lymphoma · doi:10.3109/10428199709109155 · Cited by 41
Deleu, L., Fuks, F., Spitkovsky, D., Hörlein, R., Faisst, S., & Rommelaere, J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.409 · Cited by 41
“Protein p21, but not p27, interacts with the proliferating cell nuclear antigen (PCNA) and inhibits PCNA-dependent DNA replication (29).”
BackgroundInvadopodia-mediated ECM degradation is enhanced in the G1 phase of the cell cycle
Bayarmagnai, B., Perrin, L., Pourfarhangi, K. E., Graña, X., Tüzel, E., & Gligorijevic, B. (2019) · Journal of Cell Science · doi:10.1242/jcs.227116 · Cited by 43
Zhang, Q., Wang, J., Fan, S., Wang, L., Cao, L., Tang, K., Peng, C., Li, Z., Li, W., Gan, K., et al. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.05.058 · Cited by 39
Peschiaroli, A., Figliola, R., Coltella, L., Strom, A., Valentini, A., D’Agnano, I., & Maione, R. (2002) · Oncogene · doi:10.1038/sj.onc.1206010 · Cited by 43
“Another independent function, by which p21 participates in growth arrest, involves the binding of PCNA, and inhibition of DNA replication (Luo et al., 1995).”
Backgroundp27 Modulates Cell Cycle Progression and Chemosensitivity in Human Malignant Glioma
Naumann, U., Weit, S., Rieger, L., Meyermann, R., & Weller, M. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1126 · Cited by 40
Soto, D. R., Barton, C., Munger, K., & McLaughlin-Drubin, M. E. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006661 · Cited by 39
Hughes, J., Brown, P. A., & Shankland, S. J. (1999) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1999.277.6.f948 · Cited by 39
“Unlike p27 or p57, p21 has the additional function of binding and inhibiting the proliferating cell nuclear antigen (PCNA), which plays an important role in both DNA replication and DNA repair (5, 6, 24).”
BackgroundLi, Y., Liu, J., & Li, Q. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20623 · Cited by 42
Wiebe, J. P., Beausoleil, M. S., Zhang, G., & Cialacu, V. (2009) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2009.11.005 · Cited by 38
Intestinal cell cycle regulation
Ko, T. C., Bresnahan, W. A., & Thompson, E. A. (1997) · Springer eBooks · doi:10.1007/978-1-4615-5371-7_4 · Cited by 43
Activation of the p21Waf1/Cip1Promoter by theetsOncogene Family Transcription Factor E1AF
Funaoka, K., Shindoh, M., Yoshida, K., HANZAWA, M., Hida, K., NISHIKATA, S., Totsuka, Y., & Fujinaga, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6909 · Cited by 43
Ohnishi, K., Wang, X., Takahashi, A., & Ohnishi, T. (1998) · Experimental Cell Research · doi:10.1006/excr.1997.3842 · Cited by 38
Ohsawa, Y., Okada, T., Nishimatsu, S., Ishizaki, M., Suga, T., Fujino, M., Murakami, T., Uchino, M., Tsuchida, K., Noji, S., et al. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.78 · Cited by 38
Qian, K. X., Chen, H., Wei, Y.-L., Hu, J., & Zhu, G. (2005) · Molecular Human Reproduction · doi:10.1093/molehr/gah147 · Cited by 39
“The CIP/KIP family includes three structurally related members, p21, p27 and p57 (Lee et al., 1995, 1997; Luo et al., 1995; Matsuoka et al., 1995).”
BackgroundTinkum, K. L., Marpegan, L., White, L. S., Sun, J., Herzog, E. D., Piwnica-Worms, D., & Piwnica-Worms, H. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05243-11 · Cited by 36
Regulation of replication fork speed: Mechanisms and impact on genomic stability
Merchut‐Maya, J. M., Bártek, J., & Maya‐Mendoza, A. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102654 · Cited by 39
Targeting PCNA with Peptide Mimetics for Therapeutic Purposes
Horsfall, A. J., Abell, A. D., & Bruning, J. B. (2019) · ChemBioChem · doi:10.1002/cbic.201900275 · Cited by 38
Korkolopoulou, P., Konstantinidou, A. E., Thomas-Tsagli, E., Christodoulou, P., Kapralos, P., & Davaris, P. (2000) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/00022744-200012000-00005 · Cited by 35
“To avoid any “data-driven” categorization, PCNA, Ki-67, p21, and p53 LIs entered the analysis both as continuous and dichotomous variables.”
BackgroundInfluentialAccumulation of wild-type p53 in astrocytomas is associated with increased p21 expression
Ono, Y., Tamiya, T., Ichikawa, T., Matsumoto, K., Furuta, T., Ohmoto, T., Akiyama, K., Seki, S., Ueki, K., & Louis, D. N. (1997) · Acta Neuropathologica · doi:10.1007/s004010050667 · Cited by 35
“p21 also interacts with proliferating cell nuclear antigen independent of cyclin-dependent kinases, thus participating in the control of DNA synthesis [ 23 , 37].”
BackgroundTelomerase: A Target for Anticancer Therapy
Lichtsteiner, S., LEBKOWSKI, J. S., & Vasserot, A. P. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb09395.x · Cited by 36
Jiao, S., Meng, F., Zhang, J. C., Yang, X. W., Zheng, X., & Wang, L. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1197-3 · Cited by 36
“plexes, including the ones involved in the transition between G1 and S phases, and inhibits the replication factor proliferating cell nuclear antigen (PCNA) [36].”
BackgroundThe Cdk and PCNA domains on p21Cip1both function to inhibit G1/S progression during hyperoxia
Helt, C. E., Staversky, R. J., Lee, Y., Bambara, R. A., Keng, P. C., & O’Reilly, M. A. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00243.2003 · Cited by 45
“Transient overexpression of the PCNA binding domain in R1B and U2OS cells inhibited [(3)H]thymidine and BrdU incorporation (19, 29).”
Backgroundp21 expression is a prognostic factor in patients with p53-negative gastric cancer
Xiangming, C., Hokita, S., Natsugoe, S., Tanabe, G., Baba, M., Takao, S., Kuroshima, K., & Aikou, T. (2000) · Cancer Letters · doi:10.1016/s0304-3835(99)00335-3 · Cited by 33
Tannoch, V. J., Hinds, P. W., & Tsai, L. (2002) · Advances in experimental medicine and biology · doi:10.1007/0-306-46817-4_12 · Cited by 40
Cell Cycle Control in Fission Yeast and Mammals: Identification of New Regulatory Mechanisms
Okayama, H., Nagata, A., Jinno, S., Murakami, H., Tanaka, K., & Nakashima, N. (1996) · Advances in cancer research · doi:10.1016/s0065-230x(08)60859-3 · Cited by 34
Shamanin, V. A., & Androphy, E. J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.5.2144-2152.2004 · Cited by 36
“The N terminus of p21cip1 has cdk inhibitory activity, while the C terminus binds and inhibits PCNA ( 32 ).”
BackgroundTumor Suppressor Genes and Human Cancer
Brown, M. A. (1997) · Advances in genetics · doi:10.1016/s0065-2660(08)60307-7 · Cited by 39
Responses to ultraviolet-B in cell lines from hereditary melanoma kindreds
Shannon, J., Kefford, R. F., & Mann, G. J. (2001) · Melanoma Research · doi:10.1097/00008390-200102000-00001 · Cited by 32
Metadata
- Authors
- Luo, Y., Hurwitz, J., & Massagué, J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Massagué, Joan
- Venue
- Nature
- Published
- 1995-05
- Volume
- 375
- Issue
- 6527
- Pages
- 159-161
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2030231219
- Cited by
- 549
- References
- 18
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 7 · 2021: 11 · 2020: 11 · 2019: 6 · 2018: 8 · 2017: 13 · 2016: 12 · 2015: 9 · 2014: 8 · 2013: 7 · 2012: 16
- FWCI
- 23.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p21, cyclin-dependent kinases, proliferating cell nuclear antigen, C-terminal domain, cell cycle inhibition, DNA replication inhibition, p27, p57KIP2, S phase entry
- MeSH terms
- Amino Acid Sequence, Animals, Binding Sites, Cell Cycle, DNA, Humans, Molecular Sequence Data, Recombinant Fusion Proteins, Cyclins, Protein Serine-Threonine Kinases, Proliferating Cell Nuclear Antigen, Cyclin-Dependent Kinases, CDC2-CDC28 Kinases, Cyclin-Dependent Kinase Inhibitor p21, Cyclin-Dependent Kinase 2, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.